Work

Case Report: Pembrolizumab- Induced Giant Cell Arteritis in a melanoma patient

Year: 2025

Type: article

Abstract: Background: Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. As their use has become more widespread though, rare toxicities have emerged. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumour activity in patients with advanced melanoma. Herein, we present a rare case of giant cell arteritis with an atypical presentation in a patient with stage IIIC melanoma.

Source: EJC Skin Cancer

DOI: 10.1016/j.ejcskn.2025.100572

Authors: A. Koutalopoulou, F. Ismail, E. Keen, A. Sheri

Institution: The Royal Free Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,340